The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") securities during the period between July 3, 2014 and September 9, 2016, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until December 27, 2016 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Taro securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that since 2014 the Company has worked with other pharmaceutical companies to keep the price of generic products artificially high, which violated federal antitrust laws, and that Taro's revenues during the Class Period were the result of the illegal conduct. According to the complaint, following a September 9, 2016 announcement that its subsidiary and two senior officers received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, seeking documents regarding the sale of generic pharmaceutical products, and an October 17, 2016 filing of an antitrust lawsuit against Taro and other pharmaceutical companies alleging involvement in the price-fixing of Clobetasol since 2014, the value of Taro shares declined significantly.